Tyrosine kinase targeting: A potential therapeutic strategy for diabetes
Tyrosine kinase inhibitors (TKIs) have been studied extensively in cancer research, ultimately resulting in the approval of many drugs for cancer therapy. Recent evidence from reported clinical cases and experimental studies have suggested that some of these drugs have a potential role in diabetes t...
Main Author: | Mohammad Althubiti |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Saudi Journal of Medicine and Medical Sciences |
Subjects: | |
Online Access: | http://www.sjmms.net/article.asp?issn=1658-631X;year=2022;volume=10;issue=3;spage=183;epage=191;aulast=Althubiti |
Similar Items
-
Novel Tyrosine Kinase Targets in Urothelial Carcinoma
by: Javier Torres-Jiménez, et al.
Published: (2021-01-01) -
Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
by: Manali Tilak, et al.
Published: (2021-02-01) -
Tyrosine Kinase Receptors in Oncology
by: Jorge Esteban-Villarrubia, et al.
Published: (2020-11-01) -
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01) -
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
by: Qinlian Jiao, et al.
Published: (2018-02-01)